Vaginal Intraepithelial Neoplasia (VaIN)-A Retrospective Cohort Analysis of Epidemiology, Risk Factors, and Management in an Academic Clinical Center
- PMID: 40807008
- PMCID: PMC12347765
- DOI: 10.3390/jcm14155386
Vaginal Intraepithelial Neoplasia (VaIN)-A Retrospective Cohort Analysis of Epidemiology, Risk Factors, and Management in an Academic Clinical Center
Abstract
Background: Vaginal intraepithelial neoplasia (VaIN) is a rare but potentially precancerous condition strongly associated with human papillomavirus (HPV) infection. Despite increased detection rates due to HPV screening and colposcopy, diagnosis and management remain challenging. This study aimed to evaluate the epidemiological characteristics, risk factors, and outcomes of VaIN in patients referred to a tertiary academic center. Methods: We conducted a retrospective analysis of 48 patients who underwent colposcopy-directed vaginal biopsies between January 2019 and June 2024 at the Medical University of Warsaw. Data collected included patient demographics, HPV status, cytology, histopathology, and treatment outcomes. Patients were grouped based on the presence and grade of VaIN (VaIN 1 vs. VaIN 2/3). Statistical analyses were performed using SPSS software. Results: VaIN was diagnosed in 24 patients (50%), VaIN was confirmed in half of the cohort, VaIN 2 in 30%, and VaIN 3 in 18% of cases. HPV infection and prior cervical pathology were significantly associated with VaIN diagnosis (P = 0.03 and P = 0.05, respectively), and high-risk HPV infection correlated with higher-grade lesions (P = 0.04). Among VaIN 2+ cases, most patients required laser ablation or surgical excision, while VaIN 1 often regressed spontaneously. Regression occurred in 11 cases, and high-risk HPV infection was inversely associated with spontaneous regression (P = 0.04). Conclusions: This study confirms the central role of HPV, particularly high-risk subtypes, in VaIN pathogenesis. Conservative management may be appropriate for VaIN 1, while VaIN 2+ requires active intervention. HPV genotyping should be integrated into diagnostic workups, and long-term follow-up is essential due to the risks of persistence and recurrence.
Keywords: cervical neoplasia; human papillomavirus; vaginal cancer; vaginal intraepithelial neoplasia.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Human papillomavirus infection and disease recurrence/persistence after treatment for women of high-grade cervical intraepithelial neoplasia with coexisting vaginal intraepithelial neoplasia.Front Cell Infect Microbiol. 2025 Jul 9;15:1602216. doi: 10.3389/fcimb.2025.1602216. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40703673 Free PMC article.
-
Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.Cochrane Database Syst Rev. 2016 Jan 5;2016(1):CD011837. doi: 10.1002/14651858.CD011837.pub2. Cochrane Database Syst Rev. 2016. PMID: 26728940 Free PMC article.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
The Utility of an Human Papillomavirus Genotype Assay for Cancer Screening in Self-Collected Urine and Vaginal Samples from Japanese Women.Gynecol Obstet Invest. 2025;90(2):143-152. doi: 10.1159/000541641. Epub 2024 Oct 7. Gynecol Obstet Invest. 2025. PMID: 39374596 Free PMC article.
-
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.Cochrane Database Syst Rev. 2017 Jan 26;1(1):CD009836. doi: 10.1002/14651858.CD009836.pub2. Cochrane Database Syst Rev. 2017. PMID: 28125861 Free PMC article.
References
-
- Baral S.K., Biswas P., Kaium M.A., Islam M.A., Dey D., Al Saber M., Rahaman T.I., Emran T.B., Hasan M.N., Jeong M.K., et al. A Comprehensive Discussion in Vaginal Cancer Based on Mechanisms, Treatments, Risk Factors and Prevention. Front. Oncol. 2022;12:883805. doi: 10.3389/fonc.2022.883805. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources